-
1 week ago | 
ajmc.com | Pearl Steinzor |Sanjay Goel
Ahead of the American Society of Clinical Oncology (ASCO) 2025 annual meeting, Sanjay Goel, MD, MS, professor of medicine at Robert Wood Johnson Medical School and medical oncologist at Rutgers Cancer Institute, shared his excitement for the many sessions that will be presented at this year's conference.
-
1 week ago | 
ajmc.com | Julia Bonavitacola |Pearl Steinzor |James Chalmers
James Chalmers, MD, chair of respiratory research, Cardiology, at the University of Dundee, Scotland, discussed the ways that bronchiectasis could present itself as well as how brensocatib aims to address the underlying causes of exacerbations in the condition. This transcript has been lightly edited for clarity; captions are auto-generated. TranscriptWhat is bronchiectasis and how can the condition be treated? Bronchiectasis is a chronic respiratory disease. It's common.
-
1 week ago | 
ajmc.com | Pearl Steinzor
More than one-third of colon cancer cases were diagnosed in emergency settings—particularly among patients with multiple chronic conditions, according to a study from Italy.1 These patients with colorectal cancer (CRC) were significantly less likely to be diagnosed through routine screening and more likely to experience short-term mortality, highlighting an urgent need for tailored strategies to improve early detection and outcomes.
-
2 weeks ago | 
businessandamerica.com | Pearl Steinzor
At the American Thoracic Society (ATS) 2025 International Conference, attendees shared how the conference is a representation of knowledge exchange, collaboration, and advancing medical understanding in the pulmonary and critical care fields.
-
2 weeks ago | 
ajmc.com | Pearl Steinzor
Today, the FDA approved roflumilast (Zoryve; Arcutis Biotherapeutics) topical foam 0.3% for the treatment of plaque psoriasis in adults and adolescents 12 years and older.1Roflumilast foam is a once-daily steroid-free topical which can be applied to the scalp and body. “Treating plaque psoriasis in areas like the scalp, face, and groin is especially challenging.
-
2 weeks ago | 
ajmc.com | Pearl Steinzor |Toby Maher
Nerdandomilast has the potential to become a critical new treatment option for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), offering hope where previous clinical trials have failed, says Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC. This transcript was lightly edited; captions were auto-generated. TranscriptBoth FIBRONEER trials met their primary end point of reduced forced vital capacity (FVC) decline.
-
2 weeks ago | 
ajmc.com | Pearl Steinzor |Krunal Patel
Earlier intervention is beneficial for patients with pulmonary embolism (PE), even in those with intermediate risk, which highlights the need to update the current classification system to incorporate advanced therapies like mechanical thrombectomy, says Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital. This transcript was lightly edited; captions were auto-generated.
-
2 weeks ago | 
ajmc.com | Pearl Steinzor |M. Bradley Drummond
Ensifentrine showed improved lung function, reduced exacerbations, and better patient-reported outcomes of breathing and overall chronic obstructive pulmonary disease (COPD) management, says M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill. The findings were presented at the American Thoracic Society (ATS) 2025 International Conference. This transcript was lightly edited; captions were auto-generated.
-
2 weeks ago | 
ajmc.com | Pearl Steinzor |Sanjay Ramakrishnan
Unlike the current annualized exacerbation rate, the win ratio prioritizes and combines multiple end points, such as hospitalization risk, exacerbation risk, lung function, and symptoms in chronic obstructive pulmonary disease (COPD), explains Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia. This transcript was lightly edited; captions were auto-generated.
-
3 weeks ago | 
ajmc.com | Pearl Steinzor
While medical breakthroughs have improved the health of people with diabetes, a new study finds that economic outcomes, such as employment rates and disability income reliance, have remained largely stagnant.1 The findings highlight a growing disconnect between health and financial well-being in Americans aged 40 to 64 years living with diabetes. This cross-sectional study was published in JAMA Health Forum.
